Englander Institute for Precision Medicine

Unusual Presentation of Advanced Urothelial Cancer in a Young Patient.

TitleUnusual Presentation of Advanced Urothelial Cancer in a Young Patient.
Publication TypeJournal Article
Year of Publication2025
AuthorsGuevara D, Shin N, Boiko A, Valiev I, Elsaeed AG, Mosquera JMiguel, Assaad MAl, Manohar J, Sigouros M, Zaichikova A, Fomchenkova V, Yunusova L, Smirnova S, Elemento O, Nanus D, Sternberg CN
JournalAnticancer Res
Volume45
Issue2
Pagination613-618
Date Published2025 Feb
ISSN1791-7530
KeywordsAdult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Humans, Immunotherapy, Male, Mutation, Retinoblastoma Binding Proteins, Tumor Suppressor Protein p53, Ubiquitin-Protein Ligases, Urethral Neoplasms
Abstract

BACKGROUND/AIM: Urothelial carcinoma, common in older adults, is rare in younger populations and even less common in the prostatic urethra. Advanced disease is typically managed with platinum-based chemotherapy, immune checkpoint inhibitors, and targeted therapies. However, rare presentations in young patients with aggressive disease highlight the need for innovative and personalized treatment strategies.

CASE REPORT: This case report presents a rare instance of metastatic urothelial carcinoma originating in the prostatic urethra of a 37-year-old male. Initial symptoms led to diagnosis through imaging, biopsy, and genetic profiling, revealing mutations in TP53 and RB1. The patient underwent multiple treatments, including dose-dense chemotherapy, pembrolizumab immunotherapy, and targeted antibody-drug conjugates (Enfortumab Vedotin and Sacituzumab Govitecan). Despite aggressive therapies, disease management remained challenging, leading to experimental treatments, including a personalized vaccine.

CONCLUSION: This case underscores the importance of precision medicine and the need for innovative treatment options for rare and aggressive cancers.

DOI10.21873/anticanres.17448
Alternate JournalAnticancer Res
PubMed ID39890191

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021